Russia's Sechenov First Moscow State Medical University (Sechenov University) has reportedly completed clinical trials of a coronavirus vaccine candidate developed by Gamaleya Research Institute of Epidemiology and Microbiology.
Reliable Oxygen Measurements Continuous dissolved oxygen (DO) measurement is critical during fermentation and cell culture.
Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against Covid-19.
Ridgeback Biotherapeutics has commenced enrolment for the phase 2 trial of its Covid-19 drug candidate EIDD-2801, an orally-bioavailable form of a potent ribonucleoside analog.
Clinical-stage biopharmaceutical firm Corvus Pharmaceuticals has commenced the phase 1 clinical study of novel Immunotherapy for patients with Covid-19 disease.
AVROBIO announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1.
Sunovion Pharmaceuticals said that a phase 2 study evaluating SEP-4199 as the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression) failed to meet its primary endpoint.
Sinovac Biotech ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.
Regeneron Pharmaceuticals has announced the commencement of Phase 3 trial with its investigational double-antibody cocktail REGN-COV2 to treat and prevent Covid-19 disease.
Idorsia announced positive top-line results of the second pivotal Phase 3 study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant, in 924 adult and elderly patients (39.3% ≥ 65 years) with insomnia.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.